Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
Anhui Provincial Hospital
Fujian Cancer Hospital
Henan Cancer Hospital
Fujian Cancer Hospital
Henan Cancer Hospital
Henan Cancer Hospital
Beijing Hospital
Fujian Cancer Hospital
National Cancer Center, Korea
National Cancer Center, Korea
National Cancer Center, Korea
National Cancer Center, Korea
National Cancer Center, Korea
National Cancer Center, Korea